Friday Aug 22
Diabetes Self Management
New Approach for Neuropathy Pain?
Pain from diabetic neuropathy can be debilitating for people who have the condition, and it can be difficult to treat, with only an estimated 40% to 60% of those affected achieving partial relief .
Wed Aug 20, 2014
Boston Therapeutics, Inc. Completes Enrollment Of Patients With Type ...
Boston Therapeutics, Inc. , a developer of complex carbohydrate therapeutics to treat diabetes, has completed enrollment of its Phase IIb clinical study on BTI-320 in the United States.
NuSirt Biopharma Launches First Clinical Trial
NuSirt Biopharma , Inc., is initiating a clinical trial with a goal of demonstrating whether the company's patented technology may enhance the ability of a common Type 2 diabetes medication, metformin, to control blood sugar.
Tue Aug 19, 2014
Diabetes Self Management
Metformin Study Currently Recruiting
If you have Type 2 diabetes , you may be interested in a multisite study that is currently recruiting participants to evaluate the effectiveness of an extended-release version of the oral diabetes drug metformin versus the immediate-release version of the medicine.
Fri Aug 15, 2014
Diabetes Self Management
New Metformin Combo Drug Approved for Type 2 Diabetes
On August 8, the U.S. Food and Drug Administration approved the oral combination medicine canagliflozin/metformin for Type 2 diabetes .
Thu Aug 14, 2014
Prostate Cancer and Prostatic Diseases
A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer
Prostate Cancer and Prostatic Disease 17, 252–258; doi:10.1038/pcan.2014.20; published online 27 May 2014 Correspondence: Dr AM Joshua, Division of Medical Oncology and Hematology, 610 University Avenue, Room 5-101, Toronto, ON, Canada M5G2M9.
Wed Aug 13, 2014
Metformin could make you live longer, study says
Patients who are being treated with metformin for type 2 diabetes might live longer than other people with the condition who aren't taking the drug, according to researchers at Cardiff University.
Mon Aug 11, 2014
FDA Approves Invokamet (Canagliflozin/Metformin) for Diabetes Patients
The FDA has approved Invokamet , a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type-2 diabetes.
Sun Aug 10, 2014
Invokamet For Treatment Of Type 2 Diabetes Approved
The U.S. Food and Drug Administration has approved INVOKAMETa , a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes.
Diabetes Drug, Metformin, May Increase Lifespan Of Non-Diabetics; The ...
An inexpensive and widely used medication for those with type 2 diabetes goes beyond its ability to control sugar levels and has been shown to slow down the aging process in non-diabetics.
Sat Aug 09, 2014
Association of metformin with lower atrial fibrillation risk among...
BackgroundAtrial fibrillation , an inflammatory process involving arrhythmia, is associated with severe morbidity and mortality and commonly seen in patients with diabetes mellitus .
Fri Aug 08, 2014
U.S. FDA Approves INVOKAMETa (canagliflozin/metformin HCl) for the...
INVOKAMETa provides the clinical attributes of INVOKANAA , the first sodium glucose co-transporter 2 inhibitor available in , together with metformin, which is commonly prescribed early in the treatment of type 2 diabetes.
Cardiff University Study Shows Type 2 Diabetics Can Live Longer Than People Without The Disease
Study Shows Type 2 Diabetics Can Live Longer Than People Without The Disease A commonly prescribed diabetes drug could offer surprising health benefits to non-diabetics Patients treated with a drug widely prescribed for type 2 diabetes can live longer than people without the condition, a large-scale study involving over 180,000 people has shown.
Eli Lilly Updates Jentadueto Label To Include Phase 4 Data
Eli Lilly announced that it has successfully updated the label of its Type 2 diabetes drug Jentadueto to include the latest data from a Phase IV trial showing significant blood glucose reductions.
Thu Aug 07, 2014
Glycemic Management of Type 2 Diabetes Mellitus
N Engl J Med In New England Journal of Medicine, Vol. 366, No. 14. , pp. 1319-1327, doi:10.1056/nejmcp1013127 Key Clinical Points Glycemic Control in Type 2 Diabetes Mellitus Intensive glycemic control reduces the risk of microvascular complications of type 2 diabetes, but the effect of strict glycemic control on the risk of macrovascular disease ... (more)
Diabetes drug that could help us all live longer: Doctors say it could also stave off cancer
Research suggests metformin, which controls glucose levels, may also stave off cardiovascular disease and cancer - whether someone has diabetes or not.
So just why are some patients with Type 2 diabetes living longer than those without the condition?
Patients treated with a drug widely prescribed for Type 2 diabetes can live longer than people without the condition, a large-scale study involving more than 180,000 people has shown.
Mon Aug 04, 2014
Reducing blood sugar works best with drug duo, study finds
The combined effects of metformin and SGLT2 inhibitors work best to help reduce blood sugar in diabetics more than one drug alone, report researchers in the journal Diabetes .
Applied Clinical Trials
Type 2 diabetes: Jentadueto? (linagliptin and metformin...
Type 2 diabetes: Jentadueto? tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C Type 2 diabetes: Jentadueto tablets label updated to include new data on blood glucose reductions in treatment-naive adults with high baseline A1C /PRNewswire/ -- The U.S. Prescribing Information for ... (more)
Metformin and SGLT2 inhibitors together reduce blood sugar levels
Metformin and SGLT2 inhibitors together reduce the blood sugar levels considerably more effectively than either drug alone.